Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Journal of Clinical Pathology|November 5, 2011
Two cases of opportunistic parasite infections in patients receiving alemtuzumabGuillaume Desoubeaux, Charline Caumont, Christophe Passot, et al.
Free Radical Biology & Medicine|August 20, 2005
Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidationKarine Mahéo, Sophie Vibet, Jean Paul Steghens, et al.
Annals of Hematology|November 16, 2013
Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years' experience in a single centreSinziana Radesi-Sarghi, Flavie Arbion, Caroline Dartigeas, et al.
Leukemia & Lymphoma|August 23, 2011
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?Eric Van Den Neste, Rémi Letestu, Thérèse Aurran-Schleinitz, et al.
Clinical Hematology International|September 14, 2022
FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCLCaroline Dartigeas, Borhane Slama, Margaret Doyle, et al.
Bulletin Du Cancer|October 13, 2022
[Waldenström disease: News and perspectives in 2022]Florian Bouclet, Daphné Krzisch, Véronique Leblond, et al.
Vaccines|October 26, 2021
Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic LeukemiaJulien Marlet, Philippe Gatault, Zoha Maakaroun, et al.
Ejhaem|September 29, 2025
<i>NOTCH1</i> Mutation Is Associated With Response to Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: A Retrospective StudyClémence Haméon, Roch Houot, Emmanuel Gyan, et al.
Journal of Clinical Pathology|January 6, 2016
Pulmonary toxoplasmosis in immunocompromised patients with interstitial pneumonia: a single-centre prospective study assessing PCR-based diagnosisGuillaume Desoubeaux, Églantine Cabanne, Claire Franck-Martel, et al.
Haematologica|July 7, 2018
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN studyVéronique Leblond, Melih Aktan, Christelle M Ferra Coll, et al.
Pageof 5